Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Jun;41(5):1172-1176.
doi: 10.1002/nau.24944. Epub 2022 Apr 28.

Does response to percutaneous tibial nerve stimulation predict similar outcome to sacral nerve stimulation?

Konstantinos Kapriniotis  1 , Julie Jenks  1 , Bogdan Toia  1 , Mahreen Pakzad  1 , Helena Gresty  1 , Ross Stephens  2 , Sachin Malde  2 , Arun Sahai  2 , Tamsin Greenwell  1 , Jeremy Ockrim  1
Affiliations

Does response to percutaneous tibial nerve stimulation predict similar outcome to sacral nerve stimulation?

Konstantinos Kapriniotis et al. Neurourol Urodyn. 2022 Jun.

Abstract

Aims: Percutaneous tibial nerve stimulation (PTNS) is a simple neuromodulation technique to treat an overactive bladder. It is unclear whether the response to PTNS would suggest a similar response to sacral nerve stimulation (SNS), and whether PTNS could be utilized as an alternative test phase for an SNS implant. This study assessed whether PTNS response was a reliable indicator for subsequent SNS trials.

Methods: We performed a retrospective review of the hospital databases to collect all patients who had PTNS and who subsequently had an SNS trial in two tertiary hospitals from 2014 to 2020. Response to both interventions was assessed. A 50% reduction in overactive symptoms (frequency-volume charts) was considered a positive response. McNemar's tests using exact binomial probability calculations were used. The statistical significance level was set to 0.05.

Results: Twenty-three patients who had PTNS subsequently went on to a trial of SNS. All patients except one had previously poor response to PTNS treatment. Eight of them also failed the SNS trial. However, 15 patients (including the PTNS responder) had a successful SNS trial and proceeded with the second-stage battery implantation. The difference in response rates between the PTNS and SNS trial was statistically significant (p < 0.001).

Conclusions: Poor response to PTNS does not seem to predict the likelihood of patients responding to SNS. A negative PTNS trial should not preclude a trial of a sacral nerve implant. The predictive factors for good and poor responses will be the subject of a larger study.

Keywords: percutaneous tibial nerve stimulation; sacral neuromodulation; treatment comparison.

PubMed Disclaimer

References

REFERENCES

    1. Milsom I, Abrams P, Cardozo L, Roberts RG, Thüroff J, Wein AJ. How widespread are the symptoms of an overactive bladder and how are they managed? A population-based prevalence study [published correction appears in BJU Int. 2001;88(7):807]. BJU Int. 2001;87(9):760-766.
    1. Nobrega R, Greenwell T, Pickard R, Ockrim J, Harding C. Sacral nerve stimulation versus intravesical botulinum toxin injections for medically refractory overactive bladder: a contemporary review of UK treatment from both clinician and patients' perspectives. J Clin Urol. 2018;11(5):339-344.
    1. Coyne KS, Sexton CC, Thompson CL, et al. The prevalence of lower urinary tract symptoms (LUTS) in the USA, the UK and Sweden: results from the epidemiology of LUTS (EpiLUTS) study. BJU Int. 2009;104(3):352-360.
    1. EAU Guidelines. Edn. presented at the EAU Annual Congress Milan; 2021. ISBN 978-94-92671-13-4.
    1. NICE. Urinary Incontinence in Women: Management. Guidance and Guidelines. NICE. National Institute of Health and Clinical Excellence; 2015.

MeSH terms

LinkOut - more resources